Information Provided By: 
Fly News Breaks for June 4, 2015
AZN, ARDX
Jun 4, 2015 | 07:40 EDT
Citi raised its price target for Ardelyx (ARDX) to $23 saying AstraZeneca (AZN) handing back the rights to tenapanor is a best case scenario for the company. Citi expects Ardelyx to develop tenapanor through phase 3 and then partner with an existing pharma sales force prior to approval. It estimates model peak global risk-unadjusted tenapanor sales of $1.1BB in 2030. Citi keeps a Buy rating on the stock.
News For ARDX;AZN From the Last 2 Days
AZN
Apr 26, 2024 | 11:59 EDT
AZN
Apr 26, 2024 | 11:37 EDT
AZN
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.
